 |
 |
醫(yī)學(xué)論文范文:培菲康治療前后腸易激綜合征患者相關(guān)腸道益生菌群變化分析
【摘要】 目的 觀察培菲康治療前后腸易激綜合征(IBS)患者腸道相關(guān)益生菌群的變化。方法 選取符合羅馬Ⅲ標(biāo)準(zhǔn)的IBS患者60例及年齡、性別相匹配的對(duì)照人群20人，IBS患者包括腹瀉型、便秘型、混合型、未分型4種類型，再將IBS患者隨機(jī)分為2亞組，治療組予以培菲康治療，2片，3次/d，療程為4周，對(duì)照組予以安慰劑治療4周，比較治療前后患者糞便中雙歧桿菌和乳桿菌數(shù)量的變化。結(jié)果 腹瀉型IBS患者糞便中雙歧桿菌及乳桿菌含量均小于正常人群(P<0.01)，混合型IBS患者糞便中雙歧桿菌含量小于正常人群(P<0.01);服用培菲康4周后，患者糞便中雙歧桿菌及乳桿菌含量均高于治療前(P<0.01);以腹瀉為主的IBS患者中，治療有效者，治療后糞便中雙歧桿菌和乳桿菌含量都要少于治療無效者(P<0.01)。結(jié)論 IBS患者存在某種腸道菌群的量的變化，且外源性補(bǔ)充相關(guān)益生菌制劑時(shí)，患者病情的變化伴有糞便中益生菌群的變化。
【關(guān)鍵詞】 腸易激綜合征;益生菌;熒光定量PCR;腸道菌群
Analysis of the variations of fecal probiotic microbiota in patients with irritablebowel syndrome before and after treatment with bifid
triple viable capsules
CUI Shusheng1, HU Ying2
(1. Department of Oncology, Huangpu District Central Hospital, Shanghai 200002, China;
2. Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine,
Shanghai 200092, China)
Abstract: Objective To analysis of the fecal Bifidobacterium spp. and Lactobacillus spp. in patients with irritable bowel syndrome (IBS) before and after treatment with bifid triple viable capsules for 4 weeks. Methods 60 participants with IBS, as defined by the Rome III criteria, were compared with age- and gender-matched control subjects (n=20). The IBS patients were divided into diarrhea group, constipation group, alternating group and unclassified group. The patients in the diarrhea and constipation groups were further divided into treatment group (2 capsules, 3 times daily for 4 weeks) and the control group (placebo administration for 4 weeks). The variations in the number of the fecal Bifidobacterium spp. and Lactobacillus spp. were analyzed before and after the intervention, using quantitative Real-time PCR.Results In the IBS patients with diarrhea, the amount of Bifidobacterium spp. and Lactobacillus spp. were smaller than that in healthy population (P<0.01), and in the IBS patients of alternating type, the amount of Bifidobacterium spp. was smaller than that in healthy population (P<0.01). 4 weeks after the treatment, the amounts of Bifidobacterium spp. and Lactobacillus spp. in all patients increased (P<0.01). Diarrhea-predominant IBS patients who had improvements in the Symptom Severity Score of IBS carried smaller amounts of Bifidobacterium spp. and Lactobacillus spp. than patients who had no improvement.Conclusion There are variations in the amounts of certain gut microbiota, and with exogenous replenishment of agents of probiotic microbiota, the conditions of the patients vary with the variations of fecal probiotic microbiota醫(yī).學(xué)全.在.線網(wǎng)站www.gydjdsj.org.cn.
Key words：irritable bowel syndrome; probiotics; fluorescent Real-time PCR; gut microbiota
